Диссертация (1154655), страница 26
Текст из файла (страница 26)
Salerno, F. MELD score is better than Child–Pugh score in predicting 3- monthsurvival of patients undergoing transjugular intrahepatic portosystemic shunt / F. Salerno,M. Merli, M. Cazzaniga, V. Valeriano, P. Rossi, A. Lovaria, D. Meregaglia, A. Nicolini,L.
Lubatti, O. Riggio // J Hepatol. – 2002. – vol.36. – p.494–500.180. Samsky M.D., Dunning A., DeVore A.D., Schulte P.J., Starling R.C., Wilson TangW.H., Armstrong P.W., Ezekowitz J.A., Butler J., McMurray J.J., Teerlink J.R., VoorsA.A., Metra M., Mentz R.J., O'Connor C.M., Patel C.B., Hernandez A.F. Liver functiontests in patients with acute heart failure and associated outcomes: insights fromASCEND-HF. Eur J Heart Fail. – 2016. – vol. 18(4) – 424-432.181. Samsky, M.D.
Cardiohepatic Interactions in Heart Failure An Overview and ClinicalImplications / M.D. Samsky, C.B. Patel , et al. // J Am Coll Cardiol. -2013. – vol.61. –p.2397–2405. doi: 10.1016/j.jacc.2013.03.042.182. Samuel, C.S. Relaxin remodels fibrotic healing following myocardial infarction /C.S. Samuel, S. Cendrawan, X.M. Gao, Z. Ming, C. Zhao, H. Kiriazis, Q. Xu, G.W.Tregear, R.A. Bathgate, X.J. Du // Lab Invest.
– 2011. – vol. 91. – p.675–690.183. Saner, F.H. When the heart kills the liver: acute liver failure in congestive heartfailure / F.H. Saner, M. Heuer, M. Meyer , et al. // Eur J Med Res. – 2009. – vol.14. –p.541-546. doi: 10.1186/2047-783X-14-12-541.184. Sasser, J.M. Serelaxin reduces oxidative stress and asymmetric dimethylarginine inangiotensin II-induced hypertension / J.M. Sasser, M.W. Cunningham, C.
Baylis // Am JPhysiol Renal Physiol.- 2014. – vol.307(12). – p.F1355-1362.185. Scholfield M., Schabath M.B., Guglin M. Longitudinal Trends, Hemodynamic140Profiles, and Prognostic Value of Abnormal Liver Function Tests in Patients with AcuteDecompensated Heart Failure: an Analysis of the ESCAPE Trial. J Card Fail.2014;20(7):476-84. doi: 10.1016/j.cardfail.2014.05.001.186. Scrutinio, D. Prognostic impact of comorbidities in hospitalized patients with acuteexacerbation of chronic heart failure / D. Scrutinio, A. Passantino, P.
Guida, E. Ammirati,F. Oliva, S.S. Braga, M.T. La Rovere, R. Lagioia, M. Frigerio // Eur J Intern Med. – 2016.– vol.34. – p. 63-67. doi: 10.1016/j.ejim.2016.05.020.187. Seeto, R.K.. Ischemic hepatitis: clinical presentation and pathogenesis / R.K. Seeto,B. Fenn, D.C. Rockey // Am J Med. – 2000.
– vol. 109. – p.109-113. http://dx.doi.org/10.1016/S0002-9343(00)00461-7.188. Sern Lim, H. Baseline MELD-XI score and outcome from veno-arterialextracorporeal membrane oxygenation support for acute decompensated heart failure / H.Sern Lim // Eur Heart J Acute Cardiovasc Care. – 2015. – vol. 9. pii: 2048872615610865.[Epub ahead of print]. 09 Oct 2015189. Shah, S.C. “Cardiac He - patopathy”: A review of liver dysfunction in heart failure/ S.C. Shah, D.A. Sass // Liver Res Open J.
– 2015. – vol.1(1). –p.1-10.190. Shinagawa, H. Prognostic significance of increased serum bilirubin levels coincidentwith cardiac decom- pensation in chronic heart failure / H. Shinagawa, T. Inomata, T.Koitabashi, H. Nakano, I. Takeuchi, T. Naruke, T. Ohsaka, M. Nischii, H. Takehana, T.Izumi // Circ J. – 2008. – vol.72. – p.364-369.191. Sokol, S.I. Cardiovascular drug therapy in patients with hepatic diseases and patientswith congestive heart failure / S.I.
Sokol, A. Cheng, W.H. Frishman, C.S. Kaza // J ClinPharmacol. – 2000. – vol.40. –p.11– 30.192. Stratton, A. Severe acute hepatitis following intravenous amiodarone : a case reportand review of the literature / A. Stratton, J. Fenderson, P. Kenny, D.L. Helman // ActaGastroenterol Belg. – 2015. – vol. 78(2). – p. 233-239.193. Sundaram, V.
Gastrointestinal and Liver Issues in Heart Failure / V. Sundaram, J.C.Fang // Circulation. – 2016. – vol. 133. – p. 1696-1703.194. Taniguchi, T. Usefulness of transient elastography for noninvasive and reliableestimation of right-sided filling pressure in heart failure / T. Taniguchi, Y. Sakata, T.141Ohtani, I. Mizote, Y. Takeda, Y.Asano, et al. // Am J Cardiol. – 2014. – vol.76.
– p.552– 558.195. Tapper, E.B. The Incidence and Outcomes of Ischemic Hepatitis: A SystematicReview with Meta-analysis / E.B. Tapper, N. Sengupta, A.Bonder // Am J Med. – 2015.– vol. 128(12). – p.1314-1321.196. Taylor, R.M. Short and long-term outcomes in patients with acute liver failure dueto ischemic hepatitis / R.M.
Taylor, S. Tujios, K. Jinjuvadia, et al. // Dig Dis Sci. - 2012.– vol. 57. – p. 777-785.197. Teerlink, J.R. Relaxin for the treatment of patients with acute heart failure (PreRELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dosefinding phase IIb study / J.R. Teerlink, M. Metra, G.M. Felker, et al. // Lancet. – 2009. –vol.373(9673). – p.1429–1439.198. Teerlink, J.R. Serelaxin, recombinant human relaxin-2, for treatment of acute heartfailure (RELAX-AHF): a randomised, placebo-controlled trial / J.R.
Teerlink, G. Cotter,B.A. Davison, et al. // Lancet. – 2013. – vol. 381. –p. 29–39.199. Testani, J. Clinical Characteristics and Outcomes of Patients With Improvement inRenal Function During the Treatment of Decompensated Heart Failure / J. Testani, B.McCauley, J. Chen, S. Coca, T. Cappola and S. Kimmel // Journal of Cardiac Failure.
2011. – vol.17(12). – p.993-1000.200. Testani, J. Effect of Right Ventricular Function and Venous Congestion onCardiorenal Interactions During the Treatment of Decompensated Heart Failure / J.Testani, A. Khera, M. St. John Sutton, M. Keane, S. Wiegers, R.
Shannon and J.Kirkpatrick // The American Journal of Cardiology. – 2010. – vol. 105(4). – p. 511-516.201. Tietjens, J. Serelaxin and acute heart failure / J. Tietjens, J.R. Teerlink // Heart. –2016. – vol.102. – p.95–99.202. Tokola, O. Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acidexcretion in patients with congestive heart failure / O. Tokola, O. Pelkonen, N.T. Karki,P. Luoma // Br J Clin Pharmacol.
– 1975. – vol. 2. – p.429–436.203. Uthamalingam, S. Serum albumin and mortality in acutely decompensated heartfailure / S. Uthamalingam, J. Kandala, M. Daley, et al. // Am Heart J. – 2010. – vol.160.142–p. 1149–1155. doi:10.1016/j.ahj.2010.09.004.204. Vakilian, F.
Liver Enzymes and Uric acid in Acute Heart Failure / F. Vakilian, A.A.Rafighdoost, A.H. Rafighdoost, A. Amin, M. Salehi // Res Cardiovasc Med. – 2015. –vol. 4(4). – p. e22988.205. van Deursen, V.M. Co-morbidities in patients with heart failure: an analysis of theEuropean Heart Failure Pilot Survey / V.M. van Deursen, R. Urso, C. Laroche, K.Damman, U. Dahlström, L. Tavazzi, A. Maggioni and A. Voors // Eur J Heart Fail. –2013.
– vol.16(1). – p.103-111.206. van Deursen, V.M. Liver function, in-hospital, and post-discharge clinical outcomein patients with acute heart failure-results from therelaxin for the treatment of patientswith acute heart failure study / V.M. van Deursen, C. Edwards, G. Cotter, B.A. Davison,K.I. Damman, J.R. Teerlink, M. Metra, G.M. Felker, P. Ponikowski, E. Unemori, T.Severin, A.A. Voors // J Card Fail. – 2014.
– vol.20(6). – p. 407-413.207. van Deursen, V.M. Abnormal Liver Function in Relation to Hemodynamic Profilein Heart Failure Patients / V.M. van Deursen, K. Damman, H. Hillege, A. van Beek, D.van Veldhuisen and A. Voors // Journal of Cardiac Failure. – 2010. – vol.16(1). – p..8490.208. van Deursen, V.M. Co-morbidities in heart failure / V.M. van Deursen, K. Damman,P.
van der Meer, P. Wijkstra, G. Luijckx, A. van Beek, D. van Veldhuisen and A.Voors// Heart Failure Reviews. – 2000. – vol. 19(2). – p.163-172.209. Vandenberghe, W., Gevaert, S., Kellum, J., Bagshaw, S., Peperstraete, H., Herck, I.,Decruyenaere, J. and Hoste, E. (2015). Acute Kidney Injury in Cardiorenal SyndromeType 1 Patients: A Systematic Review and Meta-Analysis. Cardiorenal Medicine, 6(2),pp.116-128. DOI:10.1159/000442300210. Varr, B.C. Maurer Emerging Role of Serelaxin in the Therapeutic Armamentariumfor Heart Failure / B.C.
Varr, M.S. Maurer // Curr Atheroscler Rep. – 2014. . – vol.16(10):447 – p.1-8.211. Verbeeck, R.K. Pharmacokinetics and dosage adjustment in patients with hepaticdysfunction. Eur J Clin Pharmacol. – 2008. – vol. 64. – p.1147-1161.212. Verbrugge, F. Abdominal Contributions to Cardiorenal Dysfunction in Congestive143Heart Failure / F. Verbrugge, M. Dupont, P. Steels, L. Grieten, M. Malbrain, W. Tangand W. Mullens // Journal of the American College of Cardiology. – 2013. – vol. 62(6).– p. 485-495.213. Verna, E.
and Wagener, G. Renal interactions in liver dysfunction and failure.Current Opinion in Critical Care. – 2013- 19(2). - pp.133-141.214. Virzì, G., Clementi, A., Brocca, A., de Cal, M., Vescovo, G., Granata, A. and Ronco,C. (2014). The Hemodynamic and Nonhemodynamic Crosstalk in Cardiorenal SyndromeType 1.
Cardiorenal Medicine, 4(2), pp.103-112.215. von Haehling, S. Ursodeoxycholic acid in patients with chronic heart failure: adouble-blind, randomized, placebo-controlled, crossover trial. / von Haehling S.,Schefold JC, Jankowska EA, Springer J, Vazir A, Kalra PR, Sandek A, Fauler G,Stojakovic T, Trauner M, Ponikowski P, Volk HD, Doehner W,Coats AJ, Poole- WilsonPA, Anker SD. // J Am Coll Cardiol.
– 2012. - 59(6). – p. 585-592.216. Vyskocilova K, Spinarova L, Spinar J, Mikusova T, Vitovec J, Malek J, Malek F,Linhart A, Fedorco M, Widimsky P, Cihalik C, Parenica J, Littnerova S, Jarkovsky J.Prevalence and clinical significance of liver function abnormalities in patients with acuteheart failure. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015. - 159(3).– p.
429-436.217. White, T.J. The liver in congestive heart failure / T.J. White, C.M. Leevy, A.M.Brusca, A.M. Gnassi // Am Heart J. – 1955. – vol. 49. – p.250–257.218. Yamazoe, M. Serum alkaline phosphatase as a predictor of worsening renal functionin patients with acute decompensated heart failure / M. Yamazoe, A. Mizuno, Y. Nishi,K. Niwa, M. Isobe // Journal of Japanese College of Cardiology.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
